Skip to content

Flatiron Health at ISPOR EU 2024

Flatiron is honored to attend and showcase our research at ISPOR EU 2024, supporting this year’s theme of “Generating Evidence Toward Health and Well-Being”

Unlock critical evidence to accelerate access to cancer treatments worldwide

At Flatiron, we are unlocking HEOR evidence and insights to demonstrate the value of oncology treatments to stakeholders including payers, regulators, and providers. By leveraging our industry leading multinational oncology data assets and expertise, we’re generating a spectrum of tailored solutions configured for the specific evidence needs of life sciences companies.

Our research explores methodological approaches and considerations for health outcomes research, use of AI and large language models to advance evidence generation, among other topics.

SCROLL TO:

Featured sessions

Workshop: Advanced Methods for Comparing Treatment Sequences or Pathways

Tuesday, November 19, 2024

10:15–11:15 AM

With an ever-increasing number of treatment options, assessing the impact of changing treatment sequences/pathways has become crucial in health technology assessment (HTA). A major challenge is the scarcity of clinical effectiveness evidence, as trials typically do not compare treatment sequences. Real-world data (RWD) offers an alternative for capturing evidence on treatment sequences but analyses require appropriate statistical methods/assumptions to address time-varying confounding and immortal time bias. Descriptive treatment pattern analyses (e.g. Sankey diagrams) are useful but do not answer the counterfactual (i.e., what-if) questions required for HTA, particularly what would have happened had patients received alternative treatment sequences and the attributable effect of different lines of treatment (LOTs).

This workshop provides an in-depth discussion on recent advances in treatment sequence evaluation in HTA, with tutorials on advanced methods for comparing treatment sequences using RWD.

discussion leader

Nicholas Latimer, PhD, MSc

University of Sheffield

panelists

Adam Brooke, MSc

National Institute for Health and Care Excellence

Blythe Adamson, PhD, MPH

Flatiron Health

Jen-Yu Amy Chang, PhD, MSc

University of Sheffield

Issue Panel: From Data to Decisions - The Potential of RWE Transportability in Healthcare Decision Making

Tuesday, November 19, 2024

1:45–2:45 PM

Health Technology Assessment (HTA) bodies increasingly consider supplementary evidence from real-world data (RWD) alongside traditional data sources like RCTs. However there remain concerns about bias and the applicability of RWD from other countries to the local settings, further complicated by the uneven availability of high-quality RWD across different geographical regions. This workshop will discuss how transportability analysis, like methods used to adjust for confounding factors, can help bridge this gap. Recently NICE updated their real-world evidence framework to include transportability methods as a potential approach to adjust for external validity concerns.

discussion leader

Blythe Adamson, PhD, MPH

Head, Outcomes Research & Evidence Generation, International at Flatiron Health

panelists

Stephen Duffield, PhD, MD

National Institute for Health and Care Excellence

Marian Eberl, MSc

Daiichi Sankyo Europe

Alexandra Starry, MPP

Cytel

Featured solutions


Accelerate market access with Flatiron’s RWE and HTA expertise

A trusted leader in oncology real-world data and evidence generation, Flatiron supports life science partners in planning and executing RWE HEOR studies, particularly in support of HTA assessments.


Filling critical evidence generation gaps with global oncology real-world data

Flatiron is a globally recognized leader in cancer-specific real-world data across the US—and now in the UK, Germany, and Japan. With deep data models encompassing unmatched biomarker variables and clinical depth, we provide rapid, compliant access to regulatory-grade data that reflects the entire patient journey.

Featured content

flatiron-forum-global-power-real-world-data

Unlocking the power of real-world data across the globe: Recent research accomplishments from Flatiron FORUM and multinational data

Flatiron FORUM

As we continue to push the boundaries of what’s possible with real-world data (RWD), I’m excited to share some of the latest research accomplishments from Flatiron Health’s FORUM and our international data initiatives. These efforts are not only advancing the field of oncology but also reshaping how we think about health technology assessments (HTAs) and global evidence generation. Here’s a glimpse into why these findings are novel and how they’re making an impact.

Read more

Blythe Adamson, PhD, MPH

Head, Outcomes Research & Evidence Generation, International, on the growing demand for local real world data in Europe and Asia

“We can now conduct cross-country studies securely, using variables that have been purpose built for harmonization and pooling.”

Flatiron experts at ISPOR EU

Arun

Arun Sujenthiran

Clinical Lead and Senior Medical Director, UK

Blythe-Adamson

Blythe Adamson

Head, Outcomes Research & Evidence Generation, International

Deepika Singh

Deepika Singh

VP, Head of Life Sciences


Our research

Read more about our accepted research at this year’s conference.

Transportability of overall survival estimates from the US to England in metastatic breast cancer using nationally representative data sources

Author affiliations: Flatiron Health, Genentech, Gilead, Pfizer, Roche

In this study, researchers evaluated the transportability of overall survival estimates from the US to the UK for metastatic breast cancer (mBC) using the US Flatiron Health EHR-derived database and the UK National Cancer Registration and Analysis Service cancer registry. This research validates transportability as a methodology for using data across borders, with the potential to improve standards of care, speed to access treatments, and provide more confidence in how medicines perform.

See this research


Date: Wednesday, November 20

Time: 9:00 AM – 11:30 AM

Poster session: 5

Poster Code: HTA359

Connect with a flatiron expert


harlan

Harlan Pittell, PhD

Senior Research Scientist

Development of oncology EHR-derived real-world data in Europe and Japan

Author affiliations: Flatiron Health

In this study, researchers showcase curated EHR-derived data sets in the UK, Germany, and Japan, demonstrating the feasibility of curating and combining real-world patient-level data across country borders within a trusted research environment in accordance with all local laws and regulations.

See this research


Date: Monday, November 18

Time: 4:00 PM – 7:00 PM

Poster session: 2

Poster Code: RWD41

Connect with a flatiron expert


Blythe-Adamson

Blythe Adamson, PhD, MPH

Head of Outcomes Research & Evidence Generation, International

Real-world data sources for oncology in five major European countries: a targeted literature review

Author affiliations: Flatiron Health

To better understand the use of real-world data to support oncology research globally, this targeted literature review evaluated published real-world data (RWD) sources for oncology during 2019-2024 in France, Germany, Italy, Spain and the United Kingdom. Researchers found that published RWD sources were primarily limited to studies designed for a specific purpose, rather than more general resources to support a variety of objectives.

See this research


Date: Monday, November 18

Time: 10:30 AM – 1:30 PM

Poster session: 1

Poster Code: RWD7

Connect with a flatiron expert


Eric Meadows

Eric Meadows

Director, Scientific Engagement

Transporting real-world evidence: Is it possible to transport OS estimates in HER2+ mBC from US to UK

Author affiliations: Flatiron Health, Genentech, Roche

This research evaluates the transportability of overall survival estimates from the U.S. to England for HER2+ metastatic breast cancer (mBC). The findings of this research indicate the U.S. overall survival estimates are a reasonable proxy for overall survival estimates in the UK HER2+ mBC population.

See this research


Date: Tuesday, November 19

Time: 10:30 AM – 1:30 PM

Poster session: 3

Poster Code: HTA219

Connect with a flatiron expert


Elsie-Horne---Data-Scientist

Elsie Horne, PhD

Quantitative Scientist

Is individual-patient data essential for transportability, or can aggregated data suffice?

Author affiliations: Flatiron Health, Genentech, Roche

In this study, researchers assessed the validity of matching-adjusted indirect comparison through a transportability study comparing the overall survival of individuals with HER2+ metastatic breast cancer (mBC) in the UK and US. This research justifies a common approach to transporting data across country borders, opening doors to further research in local areas where individual patient-level data may not be available.

See this research


Date: Monday, November 18

Time: 4:00 PM – 7:00 PM

Poster session: 2

Poster Code: RWD68

Connect with a flatiron expert


Blythe-Adamson

Blythe Adamson, PhD, MPH

Head of Outcomes Research & Evidence Generation, International

Looking for support in designing and executing HEOR studies with RWE?

Leverage Flatiron’s industry leading US and ex-US oncology data assets and expertise to drive your real-world studies, including:

  • Evaluating comparative- and cost-effectiveness

  • Modeling long-term survival

  • Examining burden of illness

  • Analyzing treatment patterns

Reach out to learn more about how we partner to accelerate patient access to oncology therapies across the globe.

Request a meeting